Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John R Petrie

Showing results (1-10 of 109) with videos related to

Pageof 11
Sort By:
Diabetes, Obesity & Metabolism|July 5, 2024
Metformin beyond type 2 diabetes: Emerging and potential new indicationsJohn R Petrie
Diabetologia|July 18, 2014
Evidence-based estimation of insulin resistanceJohn R Petrie
Cardiovascular Diabetology|September 10, 2013
The cardiovascular safety of incretin-based therapies: a review of the evidenceJohn R Petrie
Expert Opinion on Emerging Drugs|July 2, 2005
Insulin-sensitising agents: beyond thiazolidinedionesColin G Perry, John R Petrie
Biochemical Pharmacology|November 30, 2010
Implications of genome wide association studies for the understanding of type 2 diabetes pathophysiologyJohn R Petrie, Ewan R Pearson, Calum Sutherland
Current Opinion in Lipidology|June 8, 2018
Metformin, lipids and atherosclerosis preventionAlicia J Jenkins, Paul Welsh, John R Petrie
Clinical Science (London, England : 1979)|August 18, 2018
Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative reviewJames G Boyle, Rachel Livingstone, John R Petrie
Endocrine, Metabolic & Immune Disorders Drug Targets|June 13, 2009
Dissecting insulin signaling pathways: individualised therapeutic targets for diagnosis and treatment of insulin resistant statesYvonne L Woods, John R Petrie, Calum Sutherland
Diabetologia|August 4, 2017
A new perspective on metformin therapy in type 1 diabetesRachel Livingstone, James G Boyle, John R Petrie, et al.
The Canadian Journal of Cardiology|February 21, 2018
Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular MechanismsJohn R Petrie, Tomasz J Guzik, Rhian M Touyz
Pageof 11

Showing results (1-10 of 109) with videos related to

Sort By:
Pageof 11
Diabetes, Obesity & Metabolism|July 5, 2024
Metformin beyond type 2 diabetes: Emerging and potential new indicationsJohn R Petrie
Diabetologia|July 18, 2014
Evidence-based estimation of insulin resistanceJohn R Petrie
Cardiovascular Diabetology|September 10, 2013
The cardiovascular safety of incretin-based therapies: a review of the evidenceJohn R Petrie
Expert Opinion on Emerging Drugs|July 2, 2005
Insulin-sensitising agents: beyond thiazolidinedionesColin G Perry, John R Petrie
Biochemical Pharmacology|November 30, 2010
Implications of genome wide association studies for the understanding of type 2 diabetes pathophysiologyJohn R Petrie, Ewan R Pearson, Calum Sutherland
Current Opinion in Lipidology|June 8, 2018
Metformin, lipids and atherosclerosis preventionAlicia J Jenkins, Paul Welsh, John R Petrie
Clinical Science (London, England : 1979)|August 18, 2018
Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative reviewJames G Boyle, Rachel Livingstone, John R Petrie
Endocrine, Metabolic & Immune Disorders Drug Targets|June 13, 2009
Dissecting insulin signaling pathways: individualised therapeutic targets for diagnosis and treatment of insulin resistant statesYvonne L Woods, John R Petrie, Calum Sutherland
Diabetologia|August 4, 2017
A new perspective on metformin therapy in type 1 diabetesRachel Livingstone, James G Boyle, John R Petrie, et al.
The Canadian Journal of Cardiology|February 21, 2018
Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular MechanismsJohn R Petrie, Tomasz J Guzik, Rhian M Touyz
Pageof 11